Rame J Eduardo, Dries Daniel L
Division of Cardiology, University of California San Francisco, 505 Parnassus Avenue, Box 0124 M1177C, San Francisco, CA 94143-0124, USA.
Curr Treat Options Cardiovasc Med. 2007 Aug;9(4):289-301. doi: 10.1007/s11936-007-0024-3.
Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure.
左心室衰竭是多种心肌损伤的最终共同途径,包括系统性高血压和心肌梗死。虽然左心室肥厚是对压力和容量超负荷的适应性反应,但如果不进行治疗,这一过程会变得适应不良,病理性心脏肥大进而成为心力衰竭发展的一个重要且独立的危险因素。尽管其很重要,但人类从肥大到心力衰竭的转变仍知之甚少。治疗的重点应是预防心力衰竭和其他心血管事件,如中风和心房颤动。当出现心力衰竭时,药物治疗和器械治疗则着重于改善功能能力、提高生存率以及防止进展至终末期心力衰竭。